Study guide
15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding
Key Takeaways Explain This Topic AI
PALM denotes structural causes measurable by imaging or histology: polyp, adenomyosis, leiomyoma, and malignancy or hyperplasia.
COEIN denotes non-structural causes: coagulopathy, ovulatory dysfunction, endometrial, iatrogenic, and not otherwise classified.
Saline infusion sonohysterography is the modality of choice for endometrial polyps and submucosal leiomyomas.
Von Willebrand disease is the most common inherited bleeding disorder and should be considered in heavy menstrual bleeding since menarche.
The classification applies only to non-pregnant individuals of reproductive age, so a pregnancy test always precedes its use.
Last updated: September 2026
The FIGO PALM-COEIN Classification for Abnormal Uterine Bleeding
In 2011 (and updated in 2018), FIGO discarded confusing historical terms such as "menorrhagia," "metrorrhagia," "oligomenorrhea," and "dysfunctional uterine bleeding (DUB)" in favor of standardized, descriptive terminology: Abnormal Uterine Bleeding (AUB) , subclassified by the PALM-COEIN framework. The classification applies strictly to non-pregnant individuals of reproductive age. FIGO PALM-COEIN Classification Framework
- ├── Structural Causes (PALM - Measurable by Imaging or Histopathology)
- │ ├── P ──> Polyp (Endometrial or Cervical)
- │ ├── A ──> Adenomyosis (Endometrial stroma/glands in myometrium)
- │ ├── L ──> Leiomyoma (Uterine fibroids: Submucosal vs. Other)
- │ └── M ──> Malignancy & Hyperplasia (Endometrial atypical hyperplasia/cancer)
- └── Non-Structural Causes (COEIN - Not Characterized by Structural Lesions)
- ├── C ──> Coagulopathy (Systemic hemostatic disorders; e.g., vWD)
- ├── O ──> Ovulatory Dysfunction (Anovulation, irregular/unpredictable flow)
- ├── E ──> Endometrial (Primary local hemostatic or vasoconstrictive defect)
- ├── I ──> Iatrogenic (Exogenous hormones, IUDs, anticoagulants)
- └── N ──> Not Otherwise Classified (Rare or uncharacterized; e.g., AVMs)
- Structural Etiologies (PALM)
Classification Pathophysiology & Clinical Presentation Key Diagnostic Modality Nurse-Midwife Clinical Management
P - Polyp (AUB-P) Benign localized overgrowths of endometrial or endocervical glands and vascularized stroma. Common cause of intermenstrual spotting , postcoital bleeding, or light AUB. Saline Infusion Sonohysterography (SIS) or diagnostic hysteroscopy (superior sensitivity over standard 2D TVUS). Hysteroscopic polypectomy for symptomatic polyps, polyps >1.5 cm, or any polyp in postmenopausal/high-risk patients.
A - Adenomyosis (AUB-A) Ectopic presence of endometrial glands and stroma deep within the myometrium, accompanied by surrounding smooth muscle hypertrophy. Classically presents with severe secondary dysmenorrhea and heavy menstrual bleeding (HMB) in multiparous women aged 35–50. Exam reveals a symmetrically enlarged, globular, tender, "boggy" uterus . Transvaginal Ultrasound (TVUS) showing asymmetric myometrial thickening, subendometrial echogenic linear striations, myometrial cysts, and loss of distinct junctional zone. Pelvic MRI confirms equivocal cases. Levonorgestrel-releasing IUD (52 mg LNG-IUD, first-line medical therapy), continuous progestins, tranexamic acid, GnRH receptor antagonists/agonists. Definitive therapy: hysterectomy.
L - Leiomyoma / Fibroids (AUB-L) Benign monoclonal smooth muscle tumors (myomas) categorized by location: Submucosal (FIGO Types 0, 1, 2) distort the endometrial cavity and carry the highest risk of severe HMB and subfertility; Intramural (Types 3, 4, 5) within the myometrial wall; Subserosal (Types 6, 7) extend outward, causing pelvic bulk symptoms, bladder frequency, or hydronephrosis. TVUS is first-line imaging. SIS or hysteroscopy is necessary to accurately map submucosal depth and cavity distortion. Submucosal: Hysteroscopic myomectomy. Medical: 52 mg LNG-IUD, Tranexamic Acid during menses, oral GnRH antagonists with add-back therapy (elagolix, relugolix), Uterine Artery Embolization (UAE), or laparoscopic/abdominal myomectomy.
M - Malignancy & Hyperplasia (AUB-M) Endometrial hyperplasia (with or without cytological atypia) and endometrial adenocarcinoma. Endometrial atypical hyperplasia (EIN) carries a 30% to 45% risk of concurrent invasive carcinoma. Endometrial Biopsy (EMB) is the gold-standard tissue sampling tool. Diagnostic hysteroscopy with fractional dilation and curettage (D&C) if EMB is non-diagnostic or cervical stenosis precludes office biopsy. Atypical hyperplasia/carcinoma warrants urgent referral to Gynecologic Oncology. Hyperplasia without atypia is managed with high-dose progestin therapy (LNG-IUD or oral medroxyprogesterone acetate) with repeat EMB every 3 to 6 months.
Non-Structural Etiologies (COEIN)
C - Coagulopathy (AUB-C): Systemic disorders of hemostasis. Von Willebrand disease (vWD) is the most common inherited bleeding disorder, present in up to 15% to 20% of adolescents presenting with severe heavy menses since menarche. Other causes include immune thrombocytopenia (ITP), platelet dysfunction, and liver failure.
ACOG Structured Screening Tool for Coagulopathy: Screen positive if (1) Heavy menstrual bleeding since menarche, PLUS (2) One of: history of postpartum hemorrhage, surgery-related bleeding, or dental work-associated bleeding, PLUS (3) Two or more of: bruising >1–2 times/month, epistaxis >1–2 times/month, frequent gum bleeding, or family history of bleeding disorders. If positive, order CBC, PT/INR, aPTT, von Willebrand factor (vWF) antigen, ristocetin cofactor activity, and factor VIII.
O - Ovulatory Dysfunction (AUB-O): The most frequent cause of non-structural AUB in adolescents and perimenopausal individuals. In the absence of ovulation, no corpus luteum forms and no progesterone is secreted . The endometrium is subjected to continuous, chronic, unopposed estrogen stimulation, resulting in fragile, excessive vascular proliferation without structural stromal support. Eventually, the outgrown endometrium sloughs irregularly and incompletely, manifesting as unpredictable, non-cyclic bleeding that alternates between prolonged amenorrhea and massive, life-threatening hemorrhage.
Underlying Etiologies: Polycystic Ovary Syndrome (PCOS), perimenopausal HPO axis instability, hypothalamic dysfunction (extreme stress, anorexia, excessive athletic training), hyperprolactinemia, thyroid disease (both hypothyroidism and hyperthyroidism), and obesity (adipose tissue peripheral aromatization of androstenedione to estrone).
E - Endometrial (AUB-E): Occurs in ovulatory individuals with completely normal cycle regularity and duration, but objectively heavy or prolonged menses without identifiable structural lesions. Caused by primary disturbances in local endometrial molecular hemostasis: deficiency in local vasoconstrictors (endothelin-1, prostaglandin F2α) and excess production of vasodilators (prostaglandin E2, prostacyclin), or accelerated endometrial lysis of fibrin clots due to elevated levels of endometrial tissue plasminogen activator (tPA) .
I - Iatrogenic (AUB-I): Unintended bleeding secondary to medical therapies: copper IUD (increased heavy menses and cramping), levonorgestrel IUD or subdermal etonogestrel implant (unscheduled breakthrough spotting, particularly in first 3–6 months), progestin-only pills (DMPA), systemic anticoagulants (warfarin, DOACs, heparin), psychotropics that elevate prolactin (antipsychotics, SSRIs), and herbal supplements (ginkgo, ginseng, garlic).
N - Not Otherwise Classified (AUB-N): Rare or poorly understood conditions including uterine arteriovenous malformations (AVMs), myometrial hypertrophy, chronic endometritis, or isthmocele (cesarean scar defect/niche harboring trapped blood).